Dr. Matthew M. Mirsky, MD

Dr. Mirsky practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Mirsky's NPI, 1275037848, was assigned on March 20, 2018. Dr. Mirsky holds Ohio license 1275037848.

Dr. Mirsky's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Mirsky's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Mirsky is also affiliated with University Hospitals Ahuja Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Mirsky to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mirsky practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Mirsky's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Mirsky is licensed in Ohio.

CMS data shows 225 Medicare services from Dr. Mirsky across 6 procedure codes in 2024, for 87 Medicare patients. Medicare paid $16,610 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 87 Medicare patients who saw Dr. Mirsky in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mirsky's median patient age at 70, with 47% women.

In 2024, Dr. Mirsky wrote 267 Medicare Part D claims for 64 patients. 82% of them were for generic drugs. CMS names the drug for 116 of them, across 6 drugs with 11 or more claims each, at $10,986 in total drug cost. In 2019, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Mirsky for performance year 2024, reported as part of a group. Dr. Mirsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mirsky as offering telehealth.

Dmand AI links 5 papers to Dr. Mirsky, published from 2023 to 2025. 2025 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Immune Checkpoint Inhibitors. Dr. Mirsky's most frequent co-authors are Richard Hoehn, MD, Ankit Mangla, MD and Luke Daniel Rothermel.

CMS Open Payments shows 77 general payments to Dr. Mirsky from 28 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 66% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $1,957.